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Abstract
Background: Dissemination bias occurs when only some results emerging from clinical research reach their intended
audience in the knowledge translation process. Given that coverage decisions increasingly rely on evidence, it is
important to explore the types of evidence considered. This paper aimed to examine the evidence base used by
regulatory institutions involved in pricing and reimbursement of pharmaceuticals in a broad range of European
countries, as well as their awareness of and approach towards dissemination bias.
Methods: A mixed methods approach was adopted. Regulatory documents and published literature were
identified in systematic searches and relevant documents were analysed. An online survey was carried out to
verify and expand insights.
Results: Forty-two relevant regulatory documents and 10 publications were included. The survey had a 35% response
rate, yielding valid responses for 13 countries. A fragmented impression was obtained for most countries indicating a
general lack of transparency regarding both processes of decision-making and approaches towards unpublished
information. Dissemination bias was rarely consistently considered. Practices for the identification and inclusion of
all available evidence varied considerably, as did the influence of missing evidence on decision-making. Differences were
often attributable to the regulatory context and/or institutional principles.
Conclusions: Best practice is difficult to generalize given the identified variations. Individual exemplary practices support
the necessity for institutional exchange at international level. Increased institutional commitment to transparency of
methods and processes should be advocated.
Background
Dissemination bias in the knowledge translation process
occurs when “the dissemination profile of a study’s re-
sults depends on the direction or strength of its findings”
[1]. It can take different forms, most notably that of pub-
lication bias (studies with positive, statistically significant
results are favoured for publication) or selective reporting/
outcome reporting bias (for a given study, favourable out-
comes with significant effects are more likely to be re-
ported) [2]. In general, if only positive and significant
results are published, dissemination bias can lead to an
overestimation of positive effects and an underestimation
of both lack of effect and, most importantly, harm.
Thus, the partial disclosure of findings can have sub-
stantial impact on patient safety and quality of care.
Furthermore, given that decisions related to coverage
and other elements of health policy are increasingly rely-
ing on evidence, missing information can also negatively
impact areas such as resource allocation. Finally, the
partial or non-disclosure of human trials is also prob-
lematic at an ethical level. Study participants assume the
risks inherent in any experiment, at least partially with
the intent of advancing societal good (in this case the* Correspondence: dimitra.panteli@tu-berlin.de
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generation of new knowledge that will help future pa-
tients). If trial results do not flow into knowledge transla-
tion, study participants have exposed themselves to harm
without any benefit [3, 4].
The extent of the phenomenon, as well as its potential
effects, has been the focus of an increasing volume of
scientific research (indicatively [2, 5–10]). In light of a
number of initiatives towards more comprehensive and
representative evidence availability by national and inter-
national institutions, as well as the scientific community
and industry, the European Commission funded compre-
hensive research on understanding how dissemination bias
impacts different areas of the knowledge generation and
translation process in healthcare-related decision-making
and what strategies are and could be applied to address it.
In this respect, one of the aims of the 7th Framework
Programme-funded project “OPEN” was to identify prac-
tices related to publication bias on behalf of the “main
parties involved in approving, funding, conducting, pub-
lishing, and disseminating clinical research” [11]. Part of
the research carried out within the OPEN project investi-
gated dissemination bias in the context of coverage deci-
sions for pharmaceuticals. Work Package 10 examined
pricing and reimbursement processes in 36 European
countries, focusing on the role of regulatory institutions
responsible for pharmaceutical coverage, the evidence
base they use for their decisions and their awareness of
and approach towards dissemination bias. This article
presents findings from research carried out to address
the latter two points.
Methods
Rationale
The aim of this research was to capture practices in a
broad range of European countries (n = 36), including
EU Member States, candidate and accession countries
as well as the European Free Trade Association. The
practices of active regulatory institutions charged with
the assessment of and/or decision-making on the
value of pharmaceuticals for public reimbursement or
pricing at the national level were explored. Only insti-
tutions in the aforementioned countries were eligible.
Processes at regional level were not specifically tar-
geted in countries with decentralized systems, with
the exception of the United Kingdom, where the sys-
tems for England and Wales, and Scotland were stud-
ied separately.
The goal was to compile as broad a range of relevant
information as possible on a number of areas related to
the consideration of unpublished or incomplete data by
regulatory bodies responsible for coverage decisions in
European countries (Additional file 1: Table S1). A mixed
methods approach was adopted including (1) document
analysis informed by desk research and (2) a survey of
institution representatives.
Document analysis
The document analysis on institutional policies towards
publication bias included (1) a systematic search for
regulatory documents on the websites of all included in-
stitutions; (2) a systematic literature search in three da-
tabases; (3) the selection of relevant material from both
searches; (4) the extraction of information from the final
document pool; and (5) the synthesis of information and
identification of evidence gaps.
Regulatory documents (guidelines, manuals, directives,
submission requirements, etc.) were searched for in a
systematic manner using both the site map and search
function of each website to identify online information
and linked material. In parallel, literature searches were
run in PubMed, EMBASE and the Cochrane Library (see
Additional file 2 for search strategies). Inclusion criteria
for the selection of both regulatory documents and pub-
lications were specified in advance (Additional file 3:
Table S2). The reference lists of included publications
were searched to identify eligible material not captured by
the initial search. Both regulatory documents and publica-
tions were identified in April 2012. Two independent
reviewers were involved in all steps of the systematic
process and discrepancies in screening documents and
search hits for relevance were solved by discussion and
consensus. Information was extracted from all documents
using a structured extraction sheet based on the elements
in Additional file 1: Table S1. Google Translate was used
for documents that were in languages other than English,
French, German, Russian and Swedish, and interpretations
were checked by two researchers separately.
Survey of relevant institutions
To supplement the findings from the document analysis
and to ensure the completeness and validity of informa-
tion, a descriptive online survey was conducted among
included institutions. The survey was based on a struc-
tured questionnaire which was designed with the purpose
of obtaining comparable responses while minimizing ef-
fort for participants (see Additional file 4 for the full
survey tool). The content and structure of the survey
questions were developed by two researchers and reviewed
by another two, designed to correspond to the thematic
foci used to guide the document analysis. Appropriate con-
tact persons for each institution were identified by means
of author networks and online resources while additional
contacts were sought at a later point due to low response
rates. The survey was uploaded to Surveymonkey™ in
August 2012 and email invitations were sent out. Up to five
periodic reminders were sent to non-respondents until
November 2012.
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Result synthesis and presentation
Results from the document analysis and survey are
presented in a synthesized manner, organized by the-
matic focus. Country-specific information stemming
from the document analyses is followed by the coun-
try name and a reference to the corresponding docu-
ment, while for survey insights only the country name is
provided.
Results
Information yielded by the searches and survey
response rate
Overall, 105 potentially relevant regulatory documents
were identified and screened, upon which 42 were se-
lected for the analysis (see Fig. 1 for selection flow-
chart and reasons for exclusion). The systematic
database search retrieved 3,535 citations after the removal
of duplicates. Of those, 3,483 citations were excluded fol-
lowing title and abstract screening based on the pre-
specified inclusion criteria. Out of 52 remaining citations
checked for relevance in full text, 10 publications were
deemed eligible for analysis; their reference lists yielded
three additional relevant publications (see Fig. 2 for
selection flowchart and reasons for exclusion). An
overview of information availability per country is
provided in (Additional file 1: Table S1). A list of all
included regulatory documents and publications is
available in Additional file 5.
Despite repeated reminders sent to institutional
contacts for the survey, information was not forth-
coming in several cases (n = 20). Two institutions re-
plied that they would not be participating in the
project due to time constraints. In a further two cases
only the first question of the survey was filled out
with the indication of lacking knowledge on subse-
quent items. One of the respondents included in the
analysis only filled out the first two parts of the ques-
tionnaire. Overall, 13 valid responses could be proc-
essed corresponding to an approximate 35% of the 37
institutions initially contacted.
The combined efforts described above yielded infor-
mation on 26 of the 36 countries included in the ini-
tial pool. However, the extent of information varied
considerably across countries: while a comprehensive
idea could be gained for some, such as England and
Germany, only partial aspects of the topics examined
were covered for others (see in Additional file 1:
Table S1 for information availability per country).
Thus, the following sections do not provide a full in-
formation profile for each country. Quantifying state-
ments (‘most’, ‘the majority’, etc.) refer to the totality
of countries for which information was available on
each topic. Fraction denominators refer to valid re-
sponses per survey question.
Information retrieval and identification of unpublished data
General approach to evidence for coverage decisions and
submission requirements
Several institutions mentioned the methods of evidence-
based medicine as pillars that should underpin assess-
ment processes (Austria [12]; Slovakia [13]; Poland [14];
Germany [15]). All institutions participating in the survey
(13/13) declared that they attempt to identify all relevant
scientific evidence for their assessments, whether they per-
form research themselves or rely on submissions. How-
ever, non-systematic approaches are either usually or
occasionally adopted in five countries when research is
performed within the institution (Austria, Czech Republic,
Iceland, Serbia, Sweden).
Specifications on what should be included in applica-
tions in countries where the assessment is primarily
based on manufacturer submissions vary in form and
detail (Austria [16]; France [17]; Germany [15]; England
& Wales [18]; Scotland [19]; Sweden [20]). A full list of
relevant studies and definitely all studies that were used
for product authorization (licensing) are required in
most cases, while in both Germany [9, 15] and Scotland
[19] study reports and protocols should be included. Un-
published studies are required in some cases (Austria,
Germany, France, Portugal) along with ongoing trials in
France and Germany. In Luxembourg, license holders
have to provide supporting evidence in the form of at
least one study when applying for reimbursement [21],
while in Switzerland the most important studies need to
be included [22].
An overview of sources used during evaluation among re-
spondents to the survey can be found in Additional file 6:
Table S3.
Sources and types of published information
Submission requirements for manufacturers and institu-
tional method guides both specify the sources from
which information should be drawn. A minimum of two
databases is usually required for a search to be considered
systematic, while it is not always strictly specified which
two need to be chosen. The databases most frequently
mentioned can be found in Additional file 7: Table S4.
The Institute for Quality and Efficiency in Health Care
(IQWiG) in Germany [23] and the Agency for Health
Technology Assessment (AOTM) in Poland [14] explicitly
mention that systematic searches need to aim for the
highest possible sensitivity in order to ensure that no rele-
vant studies are missed.
Regarding limitations to the representativity and compre-
hensiveness of the evidence base, language of publications
(Germany [23], Ireland [24], England & Wales [18]) and
timeline of the search (Germany [25], England & Wales
[18]) are recognized as significant aspects that need to be
taken into account and documented both in cases of
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submissions and institutional research. While a number of
countries (4/13) do not enforce a language restriction for
evidence retrieval, some only include publications in Eng-
lish (Czech Republic, Malta, Serbia, England & Wales) or in
English and the country’s own language (Austria, France,
Portugal, Sweden). Iceland also includes publications in
other Nordic languages.
When institutions involved in evidence assessment
perform additional research, different approaches exist
with regard to the types of publications drawn upon
for assessment. Some institutions prioritise the utilisation
of secondary publications such as health technology as-
sessment (HTA) reports or systematic reviews and revert
to the search for primary literature if newer information is
Fig. 1 Selection of regulatory documents
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available or the evidence base provided in the secondary
sources is not deemed adequately robust (Denmark [26];
Germany [23]; Poland [14]).
Approach towards unpublished information
While all (13/13) respondents to the survey mentioned
that their institutions take published data into account
for coverage decisions (Additional file 6: Table S3),
only seven (Czech Republic, Germany, Finland, France,
Iceland, Poland, Sweden) explicitly stated that unpub-
lished information is also considered. Furthermore, the
extent to which additional effort is invested in identifying
unpublished evidence during evidence procurement varies.
The National Institute for Health and Care Excellence
Fig. 2 Selection of publications
Panteli et al. Health Research Policy and Systems  (2016) 14:6 Page 5 of 13
(NICE) in England made it necessary to include all pub-
lished and unpublished information in assessments in 2004
[27, 28]. The Irish Health Information and Quality Au-
thority also explicitly states that all attempts should be
made to identify relevant information beyond published
data [29] and the German institutions insist on an evi-
dence base as comprehensive as possible, be it in sub-
missions from the industry or in their own research
[15, 23]. Interestingly, while assessments performed by
the Association of Social Security Institutions in Austria
should attempt to capture all evidence [12], applicants
wishing to include their products in the reimbursement
list (Erstattungskodex) can limit their systematic evidence
submission to published literature [16].
As can be seen in Additional file 6: Table S3, several
methods are employed in order to identify unpublished
information. Indicatively, these include searches in trial
registries, most commonly the EU Clinical Trials Register
(5/8 responses) and ClinicalTrials.gov (4/8 responses), re-
quests to the industry and/or publication authors (Germany
[15, 23], Croatia [30], Poland [14], Turkey [31], England &
Wales [32]), and the active involvement of stakeholders
such as health professionals and manufacturers (England &
Wales [27, 32–34]). In Iceland, patient representatives are
also consulted. The search for and utilisation of grey litera-
ture is not uniformly adopted. For instance, while in some
cases conference abstracts are sought out as sources of in-
formation, other institutions specify that they are not ac-
ceptable as evidence for assessment (The Netherlands [35],
Scotland [19]).
The Haute Autorité de Santé (HAS) in France actively
seeks out the opinion of equivalent institutions in other
countries to ensure evidence completeness [17] and the
Association of Social Security Institutions in Austria
mentions the utilisation of international networks [16].
Overall, the exchange of information among institutions
determining the value of pharmaceuticals for pricing and
reimbursement purposes in the European context seems
to be taking place on a case-by-case rather than a routine
basis. National, European and international medicines
agencies are either routinely or occasionally consulted by
all institutions who responded to the survey. Information
from marketing authorization agencies required for assess-
ment usually takes the form of public assessment reports
at national or European level (European Public Assess-
ment Report; 8/10 responses), while the opinion of the
Committee for Medicinal Products for Human Use is
just as often taken into account (8/10 responses). Clinical
study reports of marketing authorisation studies are also
commonly used (6/10 responses), while study protocols are
required and included in Germany and France. Periodic
safety update reports are routinely included in Finland,
France, Slovenia and the United Kingdom while other ap-
proaches (EudraVigilance, Food and Drug Administration
Medical Reviews or Adverse Event Reporting System) are
also employed by individual institutions.
Evaluation of evidence quality and assessment of risk of bias
Information on the assessment of evidence quality ranged
from general approaches towards quality control to more
specific methodological issues and concrete measures for
checking evidence for a range of biases.
General approaches toward evidence quality included
issues such as the awareness that bias due to poor quality
of studies should be taken into consideration (Ireland
[29]) or internal and external quality checks (Austria [12]).
More specifically, while validated reporting standards such
as CONSORT and STROBE are used in France, Germany
and Portugal, checklists developed particularly for the
Norwegian context are to be used for the same purpose in
Norway [36]. These include evidence hierarchies, which are
also used in Austria, Croatia and Germany. In Germany,
both the Federal Joint Committee (G-BA) and the IQWiG
have clear guidelines on the categorization of risk of bias
for individual studies, while the latter excludes studies with
high risk of bias from its own analyses.
Specific measures related to evidence quality and po-
tential biases identified during the document analysis
include an explicit preference for peer-reviewed publi-
cations for modelling in pharmacoeconomic research
(The Netherlands [37]), standards for the comparability
of studies that can be included in indirect comparisons
and the validity of surrogate outcomes (Norway [36]),
and checking international evidence for transferability
(Croatia [30], Norway [36]).
Specific methods for identification, analysis and
presentation of unpublished information
The consistency of retrieved information is ascertained
both within the same document (8/12 responses) and
across information sources (8/12 responses). If incon-
sistencies exist, the preferred source of information
are clinical study reports in Germany, France and
Slovenia, and manufacturer submissions in the United
Kingdom, while most institutions (6/12 responses) pri-
oritise published articles. Five respondents indicated
that selective outcome reporting is controlled before the
assessment begins (Austria, Germany, France, Malta,
Sweden). Comparison between study protocols and
reports/publications (Germany) or the retrieval of the
original study material (Malta) were the specific methods
mentioned. Only two respondents indicated explicitly
checking retrieved evidence for risk of publication bias
(Germany, Portugal).
Once identified, most institutions that consider un-
published evidence (5/12 responses) use different validity
criteria for published and unpublished studies with the
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exception of Ireland [24], Finland, France and Germany.
With regard to using the data in analyses, some institutions
clearly state that missing data in meta-analyses need to be
calculated or approximated (Germany [23, 25], France [17],
Poland [14], Scotland [19, 38]). Uncertainty is explored by
means of sensitivity or sub-group analyses by some (4/12
responses: Germany, France, Portugal, Sweden). France,
Germany (IQWiG) and England include ongoing studies in
their discussion of results.
Consideration of unpublished data in the formulation of
conclusions and recommendations
The AOTM in Poland explicitly requires assessment of
whether the inclusion of only published studies can lead
to an incorrect interpretation of the review results due
to publication bias, but no specifics are given as to how
this should be achieved [14]. In Germany, the IQWiG
has a matrix to determine how bias could influence its
conclusions and recommendations [23], while the G-BA
stipulates that the additional benefit of a given drug
is considered as not proven if the submission is in-
complete or aspects of methodology or results remain
unpublished [15]; it further stipulates that the result
of sensitivity analyses based on ‘high’ or ‘low’ risk of
bias can considerably influence the institution’s con-
clusions [25]. Several respondents to the survey (7/12)
indicated that the influence of unpublished informa-
tion is to be explicitly considered when interpreting
assessment results.
Impact of incomplete evidence on decision-making
If submitted or retrieved evidence is judged to be incom-
plete, different processes are followed in different coun-
tries: most commonly, the assessment can conclude that
benefit has not been proven (9/12 responses). In other
cases, the conclusion can be negative or decision-making
overall can be postponed (9/12 responses). The post-
ponement of the assessment process and the complete
refusal of reimbursement are also possible (7/12 re-
sponses), as is the refusal of high pricing or a negative rec-
ommendation regarding the utilization of the
pharmaceutical in question (5/12 responses). Lastly,
decision-making on reimbursement and assessment can
be refused entirely (4/12 responses).
In Germany, for example, the G-BA can block an
assessment if the documents submitted by manufac-
turers are deemed incomplete [25, 39]. Meanwhile,
NICE requires manufacturers and sponsors of tech-
nologies under multiple technology appraisal to sign a
statement declaring that all material relevant to the
appraisal has been disclosed. The institute can also
terminate a single technology appraisal if there is no
or only partial evidence submitted until manufacturers
or sponsors declare that they wish to provide a full
evidence submission, upon which the appraisal can be
reinitiated. Furthermore, the Association of the British
Pharmaceutical Industry’s Code of Practice asks that
all manufacturers register all their clinical trials ac-
cording to the Joint Agreement of the International
Federation of Pharmaceutical Manufacturers and Asso-
ciations (from Phase II onwards and on a publicly
accessible website) [40].
Management of confidentiality and transparency
Information considered ‘in confidence’
Most (8/12) of the institutions who responded to the
survey accept submissions including commercial-in-
confidence data. As a rule, it is the owners/manufac-
turers who ultimately select which data will be labelled
‘in confidence’ when filing a submission, but they still
have to fully justify the need for confidentiality.
NICE only accepts submissions including commercial-
in-confidence data in exceptional cases after prior au-
thorization and expects that all information on the
methodology of a given study be in the public domain. It
further stipulates that HTA summaries are to be based
on all data and be CONSORT or PRISMA compliant [18,
40]. In Germany, while submissions to the G-BA can in-
clude confidential documentation which needs to be
marked clearly [39], the IQWiG does not accept
commercial-in-confidence data at all, asking submitting
manufacturers to sign a confidentiality waiver [41]. In
Ireland, a summary of information used in HTA should be
publicised even if the underlying data has not been fully
disclosed up to that point in order to ensure transparency
[24], whereas in the Netherlands final reports should
ideally only include public data [35].
NICE is the only institution in the sample to expli-
citly differentiate between commercial-in-confidence
and academic-in-confidence data, assuming that the
latter can be discussed during appraisal meetings des-
pite the fact that they need to not be widely publicly
disclosed in order not to prejudice the publication of
information in scientific form [40].
Publication of appraisals and results of the
decision-making process
Different approaches to ensure confidentiality while main-
taining transparency exist. The activities of the Bulgarian
Transparency Committee are announced online and a bi-
annual activity report is published on the Ministry website.
In addition, members serving on the Committee are bound
by secrecy regarding all information they become aware of
during the performance of their duties [42]. In Belgium
and France, this secrecy extends to the Committee’s secre-
tariat and external experts [43, 44]. In Germany, while the
G-BA will publish the full documentation on the appraisal
online unless there are confidentiality issues that need to
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be observed, the IQWiG makes all information, including
stakeholder views, available on its website without ex-
ception [23, 39]. The types of information disclosed to
different stakeholders among respondents to the survey
are shown in Fig. 3.
Also influencing practices in this respect is the issue of
freedom of information and its application in healthcare
and pharmaceutical appraisal. In the Swedish context,
documents kept by public authorities are public. How-
ever, both the disclosure and the privacy rule apply to
coverage decisions and therefore some information can
remain confidential. Nevertheless, it is the goal of the
Dental and Pharmaceutical Benefits Agency to design
dissemination of its decisions in such a way that they
can be fully publicised [20]. A similar situation is also
described in England, where the 2000 Freedom of Infor-
mation Act principally allows anyone to obtain informa-
tion they request from public authorities and NICE has
to consult the owner of in-confidence data to respond to
request on a case-by-case basis [40].
Management of scientific independence and potential
conflicts of interest (CoI)
The type of statement describing potential CoI and per-
sons mandated to provide it varies according to the con-
text and process of evaluation in each country. Experts
serving as consultants during the assessment or appraisal
process are most commonly obliged to report relations
(8/12 responses). Members of committees responsible
for coverage decisions are uniformly required to report
CoIs; these can lead to exclusion from the entire evalu-
ation process (7/12 responses) or a restriction in voting
rights (4/12 responses). Members of the Swiss Federal
Drug Commission (Eidgenössische Arzneimittelkommi-
sion) also need to recuse themselves upon applicant re-
quest [22]. The type of action depends on the type and
gravity of the conflict in France and Germany, while
the declaration itself is enough and no action is taken
in Austria.
All individuals participating in appraisal processes car-
ried out at the HAS in France or NICE in England need
Fig. 3 Types of data made available to different types of stakeholders by surveyed institutions. CiC, Commercial in confidence; AiC, Academic in
confidence; iC, In confidence. Numbers correspond to the number of respondents making the specific type of information available to the respective
stakeholder group
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to declare their CoI on appointment, at advisory Board
meetings and for publications. Senior staff and institute
employees at both institutions should not have (major)
pecuniary CoI [32, 45–47]. Declarations are taken down
in meeting minutes and are therefore public. However,
as a rule, CoI are not publicised (9/12 responses). Sum-
mary statements are available to the public in Germany,
Portugal and Sweden.
The HAS implements CoI declaration matrixes which
differ for external experts and employees of the institu-
tion participating in the appraisal. These are put to-
gether by a separate unit within the institution, a group
which is also responsible for looking at international best
practices on reporting CoI and amending the matrixes
accordingly. The declared CoI is taken into consider-
ation before a working group for the appraisal is formed
and eligible candidates are short-listed. HAS’s guide
cited here provides great detail on what constitutes a
major and minor, a direct and indirect CoI, and for
whom [45].
Discussion
Based on the identified institutional approaches, con-
cerns about dissemination bias were not consistently
embedded in coverage decision-making processes across
countries. Given the differences observed among formal
systems for the reimbursement and pricing of pharmaceu-
ticals in Europe, a certain degree of variation regarding
institutional practices towards procuring and evaluating
evidence for assessment and the consideration of unpub-
lished data was to be expected. It is intuitive to assume
that the level of awareness towards dissemination bias and
the inclusion of provisions for unpublished data in in-
stitutional practices may depend on the maturity and
complexity of the formal coverage system itself. How-
ever, our results show that even in well-established sys-
tems, there are not always explicit considerations on
the potential effects of unpublished data. Furthermore,
some responses to the survey indicate that questions re-
quiring background knowledge on systematic research, and
particularly those regarding specific issues on unpublished
or incomplete data, were sometimes skipped or lack of
knowledge was indicated. Thus, awareness on the existence
and meaning of dissemination bias needs to be increased
before specific measures can be taken to address the effects
of incomplete evidence in coverage decisions.
Given the varied institutional practices toward evidence-
based decision-making it is difficult to extrapolate optimal
approaches in an overarching way. This is mainly attribut-
able to the fact that existing practices are dependent not
only on the legal context in each health system but also on
previous experiences and available resources. It is, how-
ever, possible to identify exemplary aspects from the per-
spective of evidence-based decision-making. For example,
in the German system, requirements guiding the sub-
mission of documents for pricing and reimbursement
processes are not only detailed in nature but also al-
most exhaustively apply the principles of systematic
research. Meanwhile, NICE provides clear and trans-
parent directions for various stakeholders in the
health system with regard to their contribution to the
decision-making process. Likewise, the HAS approach
towards CoI and the declaration of these is detailed
and transparent. The subsequent full publication of
declarations is a unique practice among countries
where information was available and it may not be
easily transferrable to other legal contexts.
It is similarly difficult to formulate uniform recom-
mendations on issues related to unpublished data that
seem to depend on institutional principles. For example,
the acceptance of commercial-in-confidence data ranges
from excluded (IQWiG in Germany) to almost not re-
stricted (Austria, Croatia). Similarly, the utilisation of
conference abstracts and other grey literature as a sup-
plementary source of information is common practice in
some countries and ruled out in others. Great variations
seem to exist both in the number of sources used and in
the level of transparency of methods.
The consultation of trial registers, which is already
part of the process in several countries, offers a first line
of insight into unpublished information and should be
considered by institutions that do not already employ it
as routine practice. It is interesting to note that recent
research confirmed a high ratio of unpublished study re-
sults even among large clinical trials [3, 4, 48]. In response,
WHO issued a Statement on Public Disclosure of Clin-
ical Trial Results, endorsing timely and comprehensive
registration [49]. While not all unpublished studies will
necessarily have results available on the register [50], a
consistency check of the body of evidence submitted or
collected can still point towards the level of its complete-
ness and help estimate the extent to which a decision
would be taken on a sound basis [10]. The rationale behind
such consistency checks would need to allow for different
types of pharmaceuticals under evaluation – newly autho-
rized substances, for which few studies are likely to be
available, may be more prone to selective outcome report-
ing bias than publication bias. Thus, a valid consistency
check would require a comparison with study protocols or
full trial reports. Furthermore, most formal systems for
pharmaceutical coverage decisions (initially) rely on manu-
facturer submissions [51]. Therefore, a mandatory dec-
laration of full disclosure by manufacturers can be an
important step towards ensuring that all data is taken
into account in the process.
Among other national and international resources, the
European Medicines Agency (EMA) is also frequently
consulted for information. After its policy to widen
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access to trial documents was halted by the EU General
Court in spring 2013 upon objections from the industry,
the Agency issued another draft policy on the proactive
publication of trial data [52] along with a step-wise ap-
proach for the adoption of the policy to “address the risk
of possible unfair commercial use of data while ensuring
proactive and non-selective access”. Following reactions
from the scientific community on the type and extent of
proposed data access [53], the Agency revised the policy,
which was in its new form adopted in October 2014 and
became effective on January 1, 2015. The policy stipu-
lates that the EMA database, including clinical trial re-
ports submitted for marketing authorization of
medicines as of January 2015, will be made available to
the public in line with the new EU Clinical Trial Regula-
tion No 536/2014. The EMA policy acknowledges that,
while commercial in-confidence information will be
redacted before reports are made public, clinical data
can generally not fall into this category [54].
An interesting aspect coming forth from both the
document analysis and the survey is that of institutional
exchange and/or cooperation. Institutions with extensive
experience are sometimes referenced in guidelines from
corresponding institutions in other countries. In addition,
further institutions of the same national health system, or
institutions responsible for determining value in other
countries within and outside Europe as well as inter-
national HTA networks are considered as additional
sources of information for assessment. The possibility
of data sharing between regulatory institutions would
therefore facilitate evidence completeness. Taking into
consideration the differing levels of experience as well
as the multitude of approaches in place regarding pub-
lication bias, a more organised collaboration could be
advantageous, especially for institutions with limited
experience.
Finally, one of the main issues that emerged from this re-
search was the lack of transparency regarding the methods
behind evidence-based coverage decisions in many coun-
tries. Public availability of regulatory documents as well as
information from publications regarding evidence pro-
curement, evaluation and utilisation, and its impact on
decision-making, was sparse and unbalanced. This mir-
rors the general lack of transparency which characterizes
formal reimbursement processes and leaves room for im-
provement-[51]. In their framework for classifying cover-
age decision-making systems based on evidence, Hutton
et al. [55] estimated the proportion of information likely
to be publicly available on several elements of the process.
Our results more or less confirmed that, for some ele-
ments, such as general methods and responsibilities, infor-
mation is more forthcoming, while substantial gaps
remain on other areas such as transparency and
accountability.
This research provided part of the evidence base
informing a stakeholder workshop on dissemination bias
carried out in May 2013 by Cochrane Germany. The
workshop aimed to issue consensus-based recommenda-
tions for a range of key actors in the knowledge generation
and translation process. Next to general principles to
guide practice for all actors (including awareness-raising,
supporting trial registration and multi-register searches,
and endorsing rigorous methodology in scientific evidence
synthesis), specific recommendations were provided for
each group [56]. Regulatory institutions responsible for
determining the value of pharmaceuticals for coverage
were thus encouraged to:
1) make their methods and processes of benefit
assessment publicly available in order to achieve
better transparency and understanding;
2) aim for a higher degree of collaboration between
institutions to facilitate the detection of further
(unpublished) data and to foster data sharing;
3) use the full evidence base on an intervention for
their assessments;
4) (publicly) specify their course of action if they find
that the evidence base for an assessment is deemed
incomplete (e.g. no adequate proof of benefit based
on incomplete data set); and
5) request from legislators the following items which will
allow the consideration of all study results (disclosure
of full protocols and full clinical study reports):
a. a legal obligation for manufacturers to submit all
requested evidence
b. public access to EMA databases
c. public access to protocols and full study reports
In order for these recommendations to reach their full
potential and be implemented in a meaningful manner,
relevant institutions should also consider specific methodo-
logical issues emerging from this work given their remit
and resources – adopt an approach that is as systematic as
possible (e.g. regarding sources of information, evi-
dence type and language etc. – see also recommenda-
tion 3, above); consider the consistent use of specific
methods, such as funnel plots, to assess likelihood of
bias in the evidence base; consult trial registries and
perform consistency checks of submitted or identified
evidence with study protocols and/or full study reports;
and capture and publish potential conflicts of interest
for those involved in the evaluation process.
Limitations
One of the main concerns of the authors during this
project was the considerably limited amount of publicly
available information for a number of countries on the
procurement and utilization of evidence in general and,
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more specifically, their formal approach to unpublished
data. From a methodological viewpoint, this is regrettable
for a variety of reasons; existing exemplary practices may
not have been identified while practices illustrated in this
article may have been overestimated in the overall context
of fragmented information. Furthermore, a distinct lack of
information remains for a number of countries. Due to the
nature of the survey, the low response rate (13/37 institu-
tions) greatly impacted evidence completeness. Later re-
search on other topics suggests that a shorter questionnaire
administered by phone could have been more successful in
this respect. The utilization of Google Translate comes with
its own limitations as to the validity of information extrac-
tion. As data collection for this work was completed in
2012, any changes in institutional practices having come
into effect in the meantime were not taken into consider-
ation. Especially in light of newer changes at international
level (e.g. EMA policy and WHO endorsement mentioned
above), it would be interesting to revisit this issue in due
time to map relevant progress.
Conclusions
Despite the fact that the scientific community has been
increasingly aware of dissemination bias and its conse-
quences, our results showed that such concerns were
sporadically embedded in coverage decision-making pro-
cesses. There is a distinct lack of transparency regarding
both the processes of evidence-based decision-making
themselves and the consideration of unpublished data.
While underlying differences make it difficult to ex-
trapolate optimal approaches in an overarching way,
steps, such as a requirement for manufacturers to sub-
mit all data and the encouragement of actions already
taken by actors such as the EMA, can be crucial. Exem-
plary practices regarding the consideration of unpub-
lished data and ensuring transparency were identified;
in this respect, enhanced institutional collaboration
could contribute to both awareness raising and know-
ledge exchange.
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